Sign in
Not yet recruitingNo phase

Blood REST4 level as a marker of abdominal aortic aneurysm growth

Looks at whether a blood marker tracks aneurysm growth in people with abdominal aortic aneurysm.

Key facts

Who runs it
RenJi Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
REST4-AAA Registry
Status
Not yet recruiting
People taking part
70 people, planned
Started
1 Jul 2025
Expected to end
1 Jul 2031
Type of study
Observational
Treatments tested
  • mRNA level of REST4 in serum;
Record updated
9 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with an abdominal aortic aneurysm (a bulge in the main belly artery) that causes no symptoms. It studies whether a blood marker called REST4 relates to aneurysm size and growth over 5 years.

Age
50 years or more in the criteria (the registry lists a minimum age of 18 Years).
Sex
All sexes can join.
Disease stage
An aneurysm below the kidney arteries (infrarenal), with a widest diameter of 39-49 mm, without symptoms.
Earlier treatment
People cannot join if they had surgery on the aorta below the kidneys before, or got treatment in another clinical trial within 1 year.

Main reasons for not taking part

  • Past infrarenal aortic surgery, or a major surgery that is planned
  • Known aortic dissection (a tear in the aorta wall) or an inherited connective tissue disorder, known or suspected
  • Treatment with corticosteroids or other drugs that act on the whole immune system
  • Creatinine clearance (a kidney test) below 30 ml/min, significant liver disease, or HIV infection
  • Severe infection, known or suspected prostate cancer, or illness with life expectancy under 2 years

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Presence of an infrarenal AAA with a maximum diameter of 39-49 mm
  • Han nationality
  • Between 50 years or more, no gender limit
  • No mental illness
  • Subjects voluntarily participate in this study, sign an informed consent form, have good compliance, and cooperate with follow-up

Who cannot take part

  • Previous infrarenal aortic surgery
  • Planned major surgery
  • Have received any other clinical trial treatment within 1 year
  • Systemic treatment with corticosteroids or other systemic immunomodulatory therapy
  • Serious concomitant illness associated with life expectancy of less than 2 years;
  • Severe infections, including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc
  • Known or suspected inherited connective tissue disorder
  • Known or suspected prostate cancer
  • Known significant liver disease
  • Known human immunodeficiency virus infection at the time of screening;
  • Any other significant and unstable condition that could limit compliance with the trial protocol
  • Calculated creatinine clearance of less than 30 ml/min
  • Known aortic dissection

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This prospective observational study aims to investigate whether serum REST4 concentration can serve as a quantitative indicator correlated with abdominal aortic aneurysm (AAA) diameter and a predictive biomarker for AAA progression and rupture risk. Emerging evidence suggests that REST4, a splice variant of the RE-1 Silencing Transcription Factor (REST), is upregulated in vascular smooth muscle cells during AAA pathogenesis and may be released into circulation via exosomes. The study will enroll patients with asymptomatic AAA (diameter between 39-49 mm) and measure baseline serum REST4 levels, analyzing their association with morphological severity (maximum aortic diameter) and clinical outcomes (aneurysm growth rate, rupture and related mortality) through a 5-year follow-up period.

Treatments tested

  • mRNA level of REST4 in serum;

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Serum REST4 as a Predictive Biomarker for Abdominal Aortic Aneurysm Progression
Plain-language title
Blood REST4 level as a marker of abdominal aortic aneurysm growthGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
9 July 2025